Best Anxiety Medication With Least Side Effects: What Is It?

What is the best anti-anxiety drug with the least side effects?

The best anti-anxiety drug with the least side effects is the option whose likely benefits and adverse effects fit a person’s symptoms, health situation, and priorities. There is no universal winner. The National Institute of Mental Health (NIMH) says medications can affect people differently and finding one with the fewest side effects can take several tries.

For panic disorder and social anxiety, clinicians commonly start with SSRIs or other antidepressants, with the choice guided by symptoms and the patient’s situation. SSRIs and SNRIs can take several weeks to start working. NIMH lists headache, nausea, and sleep difficulty among possible effects; these are usually not severe for most people, particularly when treatment starts at a low dose and increases gradually.

Side effects also differ within a class. A systematic review and network meta-analysis by Gosmann and colleagues examined 80 studies involving 21,338 people with anxiety, obsessive-compulsive, or stress-related disorders. At least one adverse event was reported by 80.22% of participants receiving an SSRI or SNRI and 71.21% receiving placebo. Nausea was the most commonly reported event, at 25.71%, while weight change was least common, at 3.56%. These are group-level findings, not a forecast for an individual.

The useful comparison is not simply “which drug has the fewest side effects?” It is “which side effects are most relevant to this person, and which options have a pattern worth discussing?” The review found differences in overall tolerability and in autonomic, gastrointestinal, and sleep-related effects. A separate review by Gartlehner and colleagues found similar overall adverse-effect spectra across second-generation antidepressants, but different frequencies of specific effects.

Is there one anxiety medication that is considered safest for most people?

No anxiety medication is established by these sources as safest for most people. “Safe” depends on the treatment goal, the person’s medical situation, possible interactions and risks, and how they weigh particular effects against symptom relief.

The options also serve different roles. Antidepressants are daily treatments that can take several weeks to work. Buspirone is also taken daily and usually needs three to four weeks for full effect; NIMH says it is not effective when taken only as needed. NIMH’s GAD guidance describes buspirone as non-sedating and less likely to be addictive than benzodiazepines, but it can still cause unwanted effects.

Benzodiazepines can reduce severe anxiety rapidly, but prolonged use can lead to tolerance or dependence. NIMH says clinicians may prescribe them only briefly. That faster relief comes with a different trade-off from a daily treatment designed to take effect over weeks. Beta-blockers can be used for situational physical symptoms, but NIMH notes they are generally not recommended for people with asthma or diabetes.

Health conditions can change the comparison. A medicine’s general side-effect profile does not settle whether it suits someone with a particular condition or treatment history. The GAD guidance from NIMH says treatment plans depend on a person’s needs, preferences, and medical situation; psychotherapy, medication, or both can be part of treatment.

Which anxiety medications are less likely to cause sexual side effects or weight gain?

Some antidepressants have lower rates of particular side effects than others, but the evidence does not identify one medication as free of sexual or weight effects. A systematic review by Gartlehner and colleagues found paroxetine frequently had more sexual adverse effects, while bupropion had fewer. Mirtazapine and paroxetine were associated with more weight gain in the review.

The same review found other distinctions: venlafaxine was associated with more nausea and vomiting than SSRIs, while sertraline had a higher rate of diarrhea. The authors noted that evidence about rare but severe adverse events was insufficient. These comparisons describe patterns across studies. They do not predict exactly what one person will experience, and the anxiety diagnosis matters when weighing which treatments are relevant.

Buspirone may come up in a discussion about sedation: the FDA prescribing information says it lacks the prominent sedative effect associated with typical anxiolytics. In placebo-controlled trials, dizziness was reported by 12% of buspirone-treated patients and 3% of placebo recipients; nausea by 8% and 5%; and headache by 6% and 3%. The FDA label reports drowsiness in 10% of buspirone-treated patients and 9% of placebo recipients. These trial figures in the 2010 label do not mean every patient will have these effects, and the label also notes possible sexual-function effects and infrequent weight gain.

Stopping a medicine is part of the side-effect conversation. A review by Baldwin and colleagues found that escitalopram, paroxetine, and venlafaxine XR produced more discontinuation symptoms than placebo in the trials it summarized. Discontinuation profiles differed among antidepressants. The authors support reducing or stopping medication with prescriber guidance rather than abruptly.

Prepare for a medication conversation

A short list can make the comparison more specific. Bring details about earlier treatments and name the effects that would be hardest to manage during work, sleep, or daily routines.

• Describe prior medicines, the effects you noticed, and whether those effects changed over time.
• Rank your main concerns, such as sexual changes, weight change, sedation, nausea, sleep difficulty, or symptoms after stopping.
• Share other health conditions and medicines, especially conditions relevant to the options being discussed.
• Ask whether the treatment is daily or for short-term or situational relief, how long it typically takes to work, and what plan to follow if side effects appear.
• Ask how to reduce or stop a medicine safely if it proves unsuitable.